Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer

2011 ◽  
Vol 2011 ◽  
pp. 223-224
Author(s):  
T.L. Bauer
2014 ◽  
Author(s):  
Aliccia Bollig-Fischer ◽  
Shirish Gadgeel ◽  
Wei Chen ◽  
Michele Cote ◽  
Ann G. Schwartz ◽  
...  

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 8533-8533
Author(s):  
Ann G. Schwartz ◽  
Greg Dyson ◽  
Manish K. Thakur ◽  
Chrissy Lusk ◽  
Angie Wenzlaff ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 8514-8514
Author(s):  
Leyla Bayat ◽  
Pingfu Fu ◽  
Shufen Cao ◽  
Afshin Dowlati

8514 Background: While the incidence of small cell lung cancer (SCLC) has been decreasing in recent years, an increasing proportion of our patients are younger African American (AA) women. There have been no studies describing these changes as well its impact on outcome and potential genomic differences amongst white and AA populations. Methods: We maintain a clinical/genomic/pathological database of all patients with SCLC treated at our comprehensive cancer center starting from 1998. We compared the baseline characteristics and outcomes (Overall survival [OS] and progression-free survival [PFS]) between AA and white patients, and between females and males. In addition, we looked at genomic alterations in >350 cancer-related genes and compared the frequency and types of mutations in our study population. Results: A total of 917 patients with SCLC were included (median age 66 years, 486 female, 179 African American). Amongst the African American patients, 67.6% were female, a striking difference compared to the white population, where only 49.1% were women (P<0.001). In multivariable analysis, there was no association between gender or race with OS or PFS (P> 0.05). There was an increase in mutational frequency in AA women compared to both AA men and white patients. PIK3CA and KIT mutations were more frequent in females while APC mutations were more frequent in males (P=0.041 for all comparisons). There was a trend toward increased mutational frequencies in TP53, PTEN, and NOTCH1 in AA patients. The relative frequency of gene alterations is shown in the table. In univariable analysis, NOTCH1 mutation was associated with improved OS (HR 0.24 [0.06-0.96], P=0.04). Conclusions: In this large cohort of patients with SCLC followed over 2 decades, there was a striking 2-fold higher incidence of SCLC in AA females than in AA males, although there were no differences in OS or PFS by sex or race. Several genomic alterations occur in higher frequencies in AA patients and AA women, in particular, have higher mutational frequencies.[Table: see text]


2009 ◽  
Vol 27 (33) ◽  
pp. 5620-5626 ◽  
Author(s):  
Rom S. Leidner ◽  
Pingfu Fu ◽  
Bradley Clifford ◽  
Ayad Hamdan ◽  
Cheng Jin ◽  
...  

PurposePrevious studies in non–small-cell lung cancer (NSCLC) have demonstrated a wide variation in responsiveness to epidermal growth factor receptor (EGFR) –targeting agents and in genetic aberrancies of the EGFR pathway according to ethnic background, most notably a higher frequency of activating EGFR mutations among East-Asian patients. We investigated the frequency of EGFR pathway aberrancies among African American patients with NSCLC, for whom limited information presently exists.Patients and MethodsEGFR fluorescent in situ hybridization (FISH) was performed on archived tissues from 53 African American patients. Extracted DNA was sequenced for mutational analysis of EGFR exons 18 to 21 and KRAS exon 2. Results were compared by multivariate analysis to an historical control cohort of 102 white patients with NSCLC.ResultsAfrican Americans were significantly less likely to harbor activating mutations of EGFR than white patients (2% v 17%; P = .022). Only one EGFR mutation was identified, a novel S768N substitution. EGFR FISH assay was more frequently positive for African Americans than for white patients (51% v 32%; P = .018). KRAS mutational frequency did not differ between the groups (23% v 21%; P = .409).ConclusionAfrican American patients with NSCLC are significantly less likely than white counterparts to harbor activating mutations of EGFR, which suggests that EGFR tyrosine kinase inhibitors (TKIs) are unlikely to yield major remissions in this population. Our findings add to a growing body of evidence that points to genetic heterogeneity of the EGFR pathway in NSCLC among different ethnic groups and that underscores the need for consideration of these differences in the design of future trials of agents that target the EGFR pathway.


2020 ◽  
Author(s):  
April E. Deveaux ◽  
Dadong Zhang ◽  
Muthana Al Abo ◽  
Nadine J. Barrett ◽  
Rick A. Kittles ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document